Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta-analysis.
CONCLUSION: These findings demonstrated that ECZ represented the most effective and tolerable therapeutic alternative to be recommended for refractory MG. TAC may be a beneficial therapy to treat MG extensively while the efficacy of CsA and cyclophosphamide may be limited by their multiple or severe AEs.
PMID: 30809966 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - Category: Neuroscience Authors: Wang L, Huan X, Xi JY, Wu H, Zhou L, Lu JH, Zhang TS, Zhao CB Tags: CNS Neurosci Ther Source Type: research
More News: Brain | Immunotherapy | Myasthenia Gravis | Neurology | Neuroscience | Prograf | Restasis | Statistics | Study | Tacrolimus